课题基金 / 基金详情

TRANSCRIPTION REGULATION BY ONCOGENES

TRANSCRIPTION REGULATION BY ONCOGENES
癌基因的转录调控
批准号:
6102291
负责人:
Phillip A Sharp
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-05-01 至 1999-04-30

项目摘要

项目成果

Phillip A Sharp的其他基金

相似基金

相关文献

中文摘要
翻译
RNA聚合酶II对哺乳动物细胞转录的调节作用 在生物化学层面上进行研究。这方面的分析研究进展 基本过程将被用来阐明分子性质 控制恶性生长。通过序列激活转录- 特定的转录因子改变基础复合体的结构 至少由IIA IID因素组成。它的独特之处在于 将确定指定引发增长率的复合体。 转录因子与基础因子通过特异性的相互作用 蛋白质-蛋白质接触。这些蛋白质信号的化学性质 将被阐明,基本因素的表面将被联系 已确认身份。酵母菌的分析结果表明,聚合酶II 与IIA IID复合体以全酶形式结合,包含其他基本的 因素和细胞成分。类似全酶的证据将会 在哺乳动物系统中寻找。 Oct-1和Oct-2转录因子结合相同的八聚体序列 但在B细胞发育过程中起着不同的重要作用。逆转录病毒 将载体引入Oct-1和Oct-2嵌合体以确定 这种蛋白质信号决定了它们在B细胞中的独特作用。一个 用于合理设计序列特定转录的协议 以显性方式调节特定内源性的因子 基因已被提出。这一协议依赖于 序列特定的结构域,以最大限度地提高亲和力和特异性。这个 技术将通过链接器的变化进行扩展和测试 连接序列特定结构域的序列,结合的突变 锌指结构域的特异性及其与其他DNA结合的融合 域名。这一方法将通过设计一个主导因素来检验 这将刺激或抑制c-Myc和其他基因的转录。 许多癌基因和抑癌基因编码与DNA结合的蛋白质 并调节转录。体外和体内试验将用于 C-Myc,Rb-E2F型复合体转录活性的研究 Wilms‘s肿瘤因子类因子。
英文摘要
Regulation of transcription by RNA polymerase II in mammalian cells will be studied at the biochemical level. Advances in the analysis of this fundamental process will be used to elucidate the molecular nature of control of malignant growth. Activation of transcription by sequence- specific transcription factors alters the structure of a basal complex composed of at least the IIA IID factors. The unique aspect of this complex which specifies an increase rate of initiation will be determined. Transcription factors interact with basal factors through specific protein-protein contacts. The chemical nature of these protein signals will be elucidated and the surfaces of the basal factors contacted will be identified. Results from the analysis of yeast suggest that polymerase II associates with the IIA IID complex as a holoenzyme containing other basal factors and cellular components. Evidence for a similar holoenzyme will be sought in mammalian systems. The Oct-1 and Oct-2 transcription factors bind the same octamer sequence but have different essential roles during B cell development. Retroviral vectors will be used to introduce chimeras of Oct-1 and Oct-2 to determine the protein signals which determine their unique roles in B cells. A protocol for the rational design of a sequence-specific transcription factor which will regulate in a dominant fashion a specific endogenous gene has been proposed. This protocol depends upon covalent linkage of sequence-specific domains to maximize affinity and specificity. The technology will be extended and tested by variation of the linker sequences joining the sequence-specific domains, mutation of the binding specificity of the zinc finger domains and fusion of other DNA binding domains. This methodology will be tested by designing a dominant factor which will stimulate or suppress transcription of c-Myc and other genes. Many oncogenes and tumor suppressor genes encode proteins which bind DNA and regulate transcription. In vitro and in vivo assays will be used to study the transcriptional activities of c-Myc, Rb-E2F type complexes and the Wilms' tumor factor-type factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nanoformulations for siRNA Delivery to Ovarian Cancer
Characterization of Pathways Controlling Cancer at the Level of Gene Regulation
TREATMENT OF CANCER WITH siRNA DELVIERED BY NANOPARTICLES
Stress and Proliferation States Impact MicroRNA-Mediated Regulation in Cancer
海外基金